Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies.

[1]  E. Koay,et al.  Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients , 2002, Alimentary pharmacology & therapeutics.

[2]  D. Fong,et al.  Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation , 2002, Hepatology.

[3]  O. Shibolet,et al.  Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. , 2002, Blood.

[4]  Sheng-Nan Lu,et al.  Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non‐Hodgkin's lymphoma , 2002, British journal of haematology.

[5]  G. Rossi,et al.  Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy , 2001, British journal of haematology.

[6]  F. Zoulim.  Detection of hepatitis B virus resistance to antivirals. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[7]  K. Fischer,et al.  Lamivudine resistance in hepatitis B: mechanisms and clinical implications. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  W. Yeo,et al.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors , 2000, Journal of medical virology.

[9]  T. Mok,et al.  Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy , 1999, Journal of medical virology.

[10]  G. Lau,et al.  Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[12]  S. Shimano,et al.  Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  T. Motokura,et al.  Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: Survey in Japan, 1987‐1991 , 1996 .

[14]  R. Dornsife,et al.  In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans , 1996, Antimicrobial agents and chemotherapy.

[15]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .